Quantitative expression profile of PSGR in prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 1, 2006, Pages 56-61

  Xu, L L ^a   Sun, C ^a   Petrovics, G ^a   Makarem, M ^a   Furusato, B ^a   Zhang, W ^a   Sesterhenn, I A ^b   McLeod, D G ^a,c   Sun, L ^a   Moul, J W ^a,c   Srivastava, S ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

G protein coupled receptor; Gene expression; Laser capture microdissection; Prostate specific gene; Quantitative RT PCR

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN PSGR; RNA; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ARTICLE; CANCER STAGING; CAUCASIAN; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AFRICAN AMERICANS; EPITHELIAL CELLS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; LASERS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ODORANT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA PROBES; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 33644920405     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500836     Document Type: Article

References (31)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics 2004. Can Cancer J Clin 2004; 54: 8-29.
2. Small EJ. Update on the diagnosis and treatment of CaP. Curr Opin Oncol 1998; 10: 244-252.
3. Krongrad A, Lai H, Lai S. Survival after radical prostatectomy. JAMA 1997; 278: 44-46.
4. Garwick MB, Fair WR. Prostate Cancer. Scientific American, 1998, 75-83.
5. Augustus M, Moul JW, Srivastava S. The molecular phenotype of the malignant prostate. In: Srivastava S, Henson DE, Gazden A (eds). Molecular Pathology of Early Cancer. IOS press: Amsterdam, 1999; pp 321-340.
6. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA et al. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res 2000; 60: 6568-6572.
7. Mombaerts P. Seven-transmembrane proteins as odorant and chemosensory receptors. Science 1999; 286: 707-710.
8. Xia C, Ma W, Wang F, Hua Sb, Liu M. Identification of a prostate specific G-protein coupled receptor in Prostate cancer. Oncogene 2001; 20: 5903-5907.
9. Yuan TT, Toy P, McClary JA, Lin RJ, Miyamoto NG, Kretschmer PJ. Cloning and genetic characterization of an evolutionary conserved olfactory receptor that is differentially expressed across species. Gene 2001; 278: 41-51.
10. Vanti WB, Nguyen T, Cheng R, Lynch KR, George SR, O'Dowd BF. Novel human G-protein-coupled receptors. Biochem Biophys Res Commun 2003; 305: 67-71.
11. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA. Laser-capture microdissection: Opening the microscopic frontier to molecular analysis. Trends Genet 1998; 14: 272-276.
12. Best CJ, Emmert-Buck MR. Molecular profiling of tissue samples using laser capture microdissection. Expert Rev Mol Diagn 2001; 1: 53-60.
13. Rubin MA. Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer. J Pathol 2001; 195: 80-86.
14. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE et al. Allelic loss in locally metastatic, multi-sampled prostate cancer. Cancer Res 1994; 54: 273-277.
15. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Path 1995; 147: 92-101.
16. Foster CS, Bostwick DG, Bonkhoff H, Damber JE, van der Kwast T, Montironi R et al. Cellular and molecular pathology of prostate cancer precursors. Scand J Urol Nephrol 2000; 205: 19-43.
17. Isaacs W, De Marzo AD, Nelson WG. Focus on prostate cancer. Cancer Cell 2002; 2: 113-116.
18. Bauer JJ, Moul JW, McLeod DG. Prostate cancer: Diagnosis, treatment, and experience at one tertiary medical center, 1989 and 1994. Mil Med 1996; 161: 646-653.
19. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. The role of p53 tumor suppressor gene in CaP: A possible biomarker? Urology 1996; 48: 971-979.
20. Bussemakers MJ. Changes in gene expression and targets for therapy. Eur Uro 1999; 35: 408-412.
21. Lijovic M, Fabiani ME, Bader J, Frauman AG. Prostate cancer: Are new prognostic markers on the horizon? Prostate Cancer and Prostatic Dis 2000; 3: 62-65.
22. Feroze-Merzoug F, Schober MS, Chen YQ. Molecular profiling in prostate cancer. Cancer Metast Rev 2001; 20: 165-171.
23. Xu LL, Shanmugam N, Segawa T, Sesterhenn IA, McLeod DG, Moul JW et al. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics 2000; 66: 257-263.
24. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L et al. PCGEM1: A Novel Prostate Specific Gene is Overexpressed in prostate cancer. Proc Nat Acad Sci USA 2000; 97: 12216-12221.
25. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L et al. Elevated expression of PCGEMI, a prostate-specific gene with cell growth promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004; 23: 605-611.
26. Weng J, Wang J, Cai Y, Stafford LJ, Mitchell D, Ittmann M, Liu M. Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer 2005; 113: 811-818.
27. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335: 304-310.
28. Abdalla I, Ray P, Vijayakumar S. Race and serum prostate-specific antigen levels: Current status and future directions. Semin Urol Oncol 1998; 16: 207-213.
29. Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res 2000; 6: 3430-3433.
30. Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pinover WH, Hanks GE et al. Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer. Urology 2001; 58: 614-618.
31. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32: 321-325.